Literature DB >> 10744098

Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer.

J A Gietema, M T Meinardi, J Messerschmidt, T Gelevert, F Alt, D R Uges, D T Sleijfer.   

Abstract

We have shown in patients cured from metastatic testicular cancer that up to 20 years after administration of cisplatin-containing chemotherapy, circulating platinum is still detectable in plasma. This finding may influence the development of long-term, treatment-related side-effects.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10744098     DOI: 10.1016/s0140-6736(00)02044-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  39 in total

1.  Clinical and Genome-Wide Analysis of Serum Platinum Levels after Cisplatin-Based Chemotherapy.

Authors:  Matthew R Trendowski; Omar El-Charif; Mark J Ratain; Patrick Monahan; Zepeng Mu; Heather E Wheeler; Paul C Dinh; Darren R Feldman; Shirin Ardeshir-Rouhani-Fard; Robert J Hamilton; David J Vaughn; Chunkit Fung; Christian Kollmannsberger; Taisei Mushiroda; Michiaki Kubo; Robyn Hannigan; Frederick Strathmann; Lawrence H Einhorn; Sophie D Fossa; Lois B Travis; M Eileen Dolan
Journal:  Clin Cancer Res       Date:  2019-07-11       Impact factor: 12.531

2.  Impact of long-term serum platinum concentrations on neuro- and ototoxicity in Cisplatin-treated survivors of testicular cancer.

Authors:  Mette Sprauten; Thomas H Darrah; Derick R Peterson; M Ellen Campbell; Robyn E Hannigan; Milada Cvancarova; Clair Beard; Hege S Haugnes; Sophie D Fosså; Jan Oldenburg; Lois B Travis
Journal:  J Clin Oncol       Date:  2011-12-19       Impact factor: 44.544

Review 3.  Testicular cancer survivorship: research strategies and recommendations.

Authors:  Lois B Travis; Clair Beard; James M Allan; Alv A Dahl; Darren R Feldman; Jan Oldenburg; Gedske Daugaard; Jennifer L Kelly; M Eileen Dolan; Robyn Hannigan; Louis S Constine; Kevin C Oeffinger; Paul Okunieff; Greg Armstrong; David Wiljer; Robert C Miller; Jourik A Gietema; Flora E van Leeuwen; Jacqueline P Williams; Craig R Nichols; Lawrence H Einhorn; Sophie D Fossa
Journal:  J Natl Cancer Inst       Date:  2010-06-28       Impact factor: 13.506

4.  Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.

Authors:  Jorrit W van As; Henk van den Berg; Elvira C van Dalen
Journal:  Cochrane Database Syst Rev       Date:  2019-05-07

Review 5.  Arterial events in cancer patients-the case of acute coronary thrombosis.

Authors:  Ohad Oren; Joerg Herrmann
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

6.  Lower cognitive performance and white matter changes in testicular cancer survivors 10 years after chemotherapy.

Authors:  Myrle M Stouten-Kemperman; Michiel B de Ruiter; Matthan W A Caan; Willem Boogerd; Martijn J Kerst; Liesbeth Reneman; Sanne B Schagen
Journal:  Hum Brain Mapp       Date:  2015-08-25       Impact factor: 5.038

Review 7.  Vascular Toxicities of Cancer Therapies: The Old and the New--An Evolving Avenue.

Authors:  Joerg Herrmann; Eric H Yang; Cezar A Iliescu; Mehmet Cilingiroglu; Konstantinos Charitakis; Abdul Hakeem; Konstantinos Toutouzas; Massoud A Leesar; Cindy L Grines; Konstantinos Marmagkiolis
Journal:  Circulation       Date:  2016-03-29       Impact factor: 29.690

8.  Different infusion durations for preventing platinum-induced hearing loss in children with cancer.

Authors:  Jorrit W van As; Henk van den Berg; Elvira C van Dalen
Journal:  Cochrane Database Syst Rev       Date:  2020-01-21

9.  New approach to tumor therapy for inoperable areas of the brain: chronic intraparenchymal drug delivery.

Authors:  Benjamin S Carson; Qingze Wu; Betty Tyler; Lindsey Sukay; Ratul Raychaudhuri; Francesco DiMeco; Richard E Clatterbuck; Alessandro Olivi; Michael Guarnieri
Journal:  J Neurooncol       Date:  2002-11       Impact factor: 4.130

Review 10.  Vascular toxic effects of cancer therapies.

Authors:  Joerg Herrmann
Journal:  Nat Rev Cardiol       Date:  2020-03-26       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.